trending Market Intelligence /marketintelligence/en/news-insights/trending/b5ElcyegLY4r77auCrxM4A2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Roche, Sarepta sign $1.15B license deal on Duchenne muscular dystrophy drug

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Roche, Sarepta sign $1.15B license deal on Duchenne muscular dystrophy drug

Roche Holding AG agreed to acquire rights to launch and commercialize Sarepta Therapeutics Inc.'s Duchenne muscular dystrophy therapy SRP-9001 outside the U.S.

Roche will pay $750 million in cash upfront and another $400 million for Sarepta common shares at $158.59 apiece, the Cambridge, Mass.-based biotech company said in a Dec. 23 press release. Sarepta will also be eligible to receive up to $1.7 billion in milestone payments tied to regulatory approvals and sales, in addition to royalties on net product sales.

SRP-9001 is being developed by Sarepta to treat Duchenne muscular dystrophy, a genetic disorder characterized by progressive muscle degeneration and weakness.

The deal is expected to close in the first quarter of 2020.

The Switzerland-based pharmaceutical giant will undertake half of the expenses related to the clinical development of SRP-9001 while Sarepta will continue to manufacture the drug, Sarepta added.

Goldman Sachs & Co LLC is the lead financial adviser to Sarepta for the transaction, while Morgan Stanley & Co LLC is the financial adviser and Ropes & Gray LLP is the legal adviser.

SRP-9001 previously caused an adverse reaction in a boy enrolled in a clinical study evaluating the therapy in male patients ages 4 to 7 years old over 48 weeks, plus a 96-week extension study, according to a U.S. Food and Drug Administration's report in August.